Your browser doesn't support javascript.
loading
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Gärtner, Jutta; Hauser, Stephen L; Bar-Or, Amit; Montalban, Xavier; Cohen, Jeffrey A; Cross, Anne H; Deiva, Kumaran; Ganjgahi, Habib; Häring, Dieter A; Li, Bingbing; Pingili, Ratnakar; Ramanathan, Krishnan; Su, Wendy; Willi, Roman; Kieseier, Bernd; Kappos, Ludwig.
  • Gärtner J; Department of Paediatrics and Adolescent Medicine, Division of Paediatric Neurology, University Medical Centre Göttingen, Georg August University Göttingen, Göttingen, Germany.
  • Hauser SL; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California - San Francisco, San Francisco, CA, USA.
  • Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Montalban X; Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Cohen JA; Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Cross AH; Department of Neurology, Section of Neuroimmunology, Washington University School of Medicine, St Louis, MO, USA.
  • Deiva K; Department of Pediatric Neurology, University Hospitals Paris Saclay, Hôpital Bicêtre, National Reference Center for Rare Inflammatory Brain and Spinal Diseases, Le Kremlin-Bicêtre, France.
  • Ganjgahi H; Oxford Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Population Health, University of Oxford, Oxford, UK/Statistics Department, University of Oxford, Oxford, UK.
  • Häring DA; Novartis Pharma AG, Basel, Switzerland.
  • Li B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Pingili R; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Ramanathan K; Novartis Pharma AG, Basel, Switzerland.
  • Su W; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Willi R; Novartis Pharma AG, Basel, Switzerland.
  • Kieseier B; Novartis Pharma AG, Basel, Switzerland.
  • Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, and Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital of Basel, University of Basel, Basel, Switzerland.
Mult Scler ; 28(10): 1562-1575, 2022 09.
Article en En | MEDLINE | ID: mdl-35266417
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article